Physician profile
Ashley Van Lith
NPI 1356936074
$3,510.93
in general payments reported to CMS, 2019-2025
23 companies · $20.43 in 2025
The $20.43 reported for 2025 was less than what a typical Acute Care (Nurse Practitioner) provider received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $320 · 2022: $1,900 · 2023: $1,271 · 2025: $20.43.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,291.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,291.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,106.43 | 2021-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $515.99 | 2021-2023 | Xifaxan, Trulance |
| Celgene Corporation | $271.49 | 2021-2023 | Zeposia |
| Qol Medical, LLC | $262.88 | 2021-2023 | Sucraid |
| Takeda Pharmaceuticals U.S.A., INC. | $239.78 | 2022-2023 | Entyvio |
| Genzyme Corporation | $205.23 | 2022-2023 | |
| Janssen Biotech, INC. | $154.54 | 2022-2023 | Stelara |
| E.R. Squibb & Sons, L.L.C. | $135.00 | 2023 | Zeposia |
| Braintree Laboratories, INC. | $119.81 | 2022-2023 | Suflave, Sutab |
| Gilead Sciences, INC. | $107.10 | 2022 | |
| Nestle Healthcare Nutrition INC. | $74.75 | 2021-2022 | |
| Amgen INC. | $54.12 | 2022 | |
| Ardelyx, INC. | $53.04 | 2022-2023 | Ibsrela |
| Ironwood Pharmaceuticals, INC | $42.86 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $23.55 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $23.36 | 2021-2022 | |
| Mallinckrodt Hospital Products INC. | $20.43 | 2025 | Terlivaz |
| Vivus LLC | $18.96 | 2023 | Qsymia |
| Ultragenyx Pharmaceutical INC. | $18.24 | 2022 | |
| Pfizer INC. | $17.20 | 2023 | |
| Merck Sharp & Dohme LLC | $15.56 | 2021 | |
| Alnylam Pharmaceuticals INC. | $15.48 | 2021 | |
| Intra-Sana Laboratories | $15.13 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Van Lith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.